Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 107-114

  Suciu, Cristian ^a,b   Muresan, Anca ^a,b   Cornea, Remus ^a   Suciu, Oana ^c   Dema, Alis ^a,b   Raica, Marius ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b Emergency County Hospital   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chemotherapy; Counting method; Invasive ductal carcinoma; Ki 67 index; Luminal carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER MORPHOLOGY; CANCER STAGING; CELL DENSITY; CLINICAL ASSESSMENT; CLINICAL FEATURE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORPHOMETRICS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84888400668     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1654     Document Type: Article

References (45)

1. Siegel R, Naishadham D and Jemal A: Cancer Statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist 9: 606-616, 2004.
3. Tavassoli FA and Devilee P (eds): TNM classification of carcinomas of the breast. In: World Health Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, pp11-12, 2003.
4. Rosen PP (ed): Invasive duct carcinoma: assessment of prognosis, morphologic prognostic markers, and tumor growth rate. In: Rosen's Breast Pathology. 3rd edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp358-404, 2009.
5. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
6. Goldhirsch A, Wood WC, Coates AS, et al: Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncology 22: 1736-1747, 2011.
7. Carey L, Perou CM, Livasy CA, et al: Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
8. Mullan PB and Millikan RC: Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci 64: 3219-3232, 2007.
9. Dowsett M, Nielsen OT, A'Hern R, et al; International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664, 2011.
10. Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23: 7212-7220, 2005.
11. Goldhirsch A, Ingle JN, Gelber RD, et al: Panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
12. Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
13. Varga Z, Diebold J, Dommann-Scherrer C, et al: How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-and Gynecopathologists. PLoS One 7: e37379, 2012.
14. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978, 2000.
15. Edge SB, Byrd DR, Compton CC, et al (eds): Breast. In: AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, pp345-376, 2010.
16. Derek AC (ed): Breast carcinoma. In: Histopathology Reporting. Guidelines for Surgical Cancer. Springer-Verlag, London, pp213-235, 2006.
17. Moinfair F (ed): Infiltrating ductal carcinoma (NOS type). In: Essentials of Diagnostic Breast Pathology. A Practical Approach. Springer Berlin Heidelberg, New York, NY, pp180-181, 2007.
18. Rakha EA, Reis-Filho JS, Baehner F, et al: Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12: 207, 2010.
19. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
20. Dunne B and Going JJ: Scoring nuclear pleomorphism in breast cancer. Histopathology 39: 259-265, 2001.
21. Elston CW and Ellis IO (eds): Assessment of histological gradee. In: Systemic Pathology. The Breast. Vol. 13. 3rd edition. Churchill Livingstone, Philadelphia, PA, pp365-384, 1998.
22. Rampaul RS, Pinder SE, Elston CW and Ellis IO; Nottingham Breast Team: Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 27: 229-238, 2001.
23. Wolff AC, Hammond HE, Schwartz JN, et al; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007.
24. Rakha EA, Elsheikh SE, Aleskandarany MA, et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310, 2009.
25. Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
26. Beresford MJ, Wilson GD and Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8: 216, 2006.
27. Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
28. du Manoir S, Guillaud P, Camus E, et al: Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12: 455-463, 1991.
29. Bruno S and Darzynkiewicz Z: Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25: 31-40, 1992.
30. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
31. Park D, Kåresen R, Noren T and Sauer T: Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch 451: 11-18, 2007.
32. Aleskandarany MA, Green AR, Benhasouna AA, et al: Prognostic value of proliferation assay in the luminal, HER2-positive and triple-negative biologic classes of breast cancer. Breast Cancer Res 14: R3, 2012.
33. Luporsi E, André F, Spyratos F, et al: Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132: 895-915, 2012.
34. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750, 2009.
35. Yamaguchi T and Mukai H: Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial. Jpn J Clin Oncol 42: 1211-1214, 2012.
36. Jalava P, Kuopio T, Juntti-Patinen L, et al: Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48: 674-682, 2006.
37. Arber DA: Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10: 183-186, 2002.
38. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000.
39. DiVito KA, Charette LA, Rimm DL and Camp RL: Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84: 1071-1078, 2004.
40. Boon ME: Microwave-antigen retrieval: the importance of pH of the retrieval solution for MIB-1 staining. Eur J Morphol 34: 375-379, 1996.
41. Mengel M, von Wasielewski R, Wiese B, et al: Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198: 292-299, 2002.
42. Faratian D, Munro A, Twelves C and Bartlett JM: Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 54: 254-257, 2009.
43. Tawfik O, Kimler BF, Davis M, et al: Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. Virchows Arch 450: 627-636, 2007.
44. Viale G, Giobbie-Hurder A, Regan MM, et al; Breast International Group Trial 1-98: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575, 2008.
45. Mohammed ZM, McMillan DC, Elsberger B, et al: Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 106: 383-388, 2012.